Physician profile
Laura E Boggs
NPI 1013105949
$1,661.32
in general payments reported to CMS, 2019-2025
22 companies · $591 in 2025
The $591 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $67.73 · 2022: $96.96 · 2023: $138 · 2024: $485 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,213.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $313.53 | 2019-2025 | Wegovy |
| Madrigal Pharmaceuticals | $185.21 | 2024-2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $183.33 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $122.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Phathom Pharmaceuticals, INC. | $90.81 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $89.47 | 2019-2022 | |
| Lilly USA, LLC | $87.05 | 2019-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $69.67 | 2023-2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $58.10 | 2025 | Rexulti |
| Lundbeck LLC | $51.13 | 2024-2025 | Rexulti |
| Abbvie INC. | $50.20 | 2019-2025 | |
| Pfizer INC. | $48.84 | 2019-2025 | |
| Exact Sciences Corporation | $48.16 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $47.81 | 2019 | |
| Baxter Healthcare | $44.71 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.77 | 2022-2023 | Xarelto |
| Verona Pharma, INC. | $29.50 | 2025 | Ohtuvayre |
| Amgen INC. | $24.04 | 2025 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $20.15 | 2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $20.08 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.82 | 2025 | |
| Sunovion Pharmaceuticals INC. | $17.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Boggs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.